INTEGRATED DRUG CREATION
Live / Applied — Non-final action mailed (as of 25 Mar 2026)
What this means for you
Not registered yet, but its 17 Feb 2026 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 99656789
- Mark type
- Stylized text
- Filed
- 17 Feb 2026
- Attorney of record
- Tiffany D. Gehrke
Goods and services
- Class 040 — Treatment of materials: Biotechnological services, namely, custom production and purification of biotechnological and pharmaceutical preparations, namely, hormones, antibodies, and proteins; biotechnological services, namely, custom production of cell lines to produce proteins, such as hormones, cytokines, antibodies and antibody fragments
- Class 042 — Scientific and technological services: Scientific and technological consulting services relating to producing, assaying, and purifying biotechnological products; research and development in the pharmaceutical and biotechnology fields; services of biotechnical and pharmacological laboratories, namely, scientific and technological research relating to the production of biotechnological products for use in preparing pharmaceutical preparations; scientific and technological research relating to the production of biotechnological products for use in preparing pharmaceutical preparations, and scientific consultation related thereto; scientific research, namely, carrying out feasibility studies relating to the production of biotechnological products for use in preparing pharmaceutical preparations; discovery of pharmaceutical preparations, medicines and medicaments; technological services, namely, technological consultation relating to the production of biotechnological products for use in preparing pharmaceutical preparations; Bioinformatics research services, namely, analyzing complex biological data through the use of artificial intelligence, and testing and evaluation of biologics through artificial intelligence; computer assisted biologics design involving the use of artificial intelligence technology; Biotechnological services, namely, discovery of biotechnological and pharmaceutical preparations, namely, hormones, antibodies, and proteins; biotechnological services, namely, discovery of cell lines to produce proteins, such as hormones, cytokines, antibodies and antibody fragments
Owner
- Absci Corporation, Vancouver, WA, US
Prosecution history
- 25 Mar 2026 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 25 Mar 2026 — NON-FINAL ACTION E-MAILED
- 25 Mar 2026 — NON-FINAL ACTION WRITTEN
- 23 Mar 2026 — ASSIGNED TO EXAMINER
- 17 Feb 2026 — APPLICATION FILING RECEIPT MAILED
- 17 Feb 2026 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 17 Feb 2026 — NEW APPLICATION ENTERED